论文部分内容阅读
目的评价两种口服辛伐他汀片治疗高脂血症的成本-效果。方法运用药物经济学成本分析的方法将高血脂门诊患者共112例,随机分为两组,分别给予京必舒新与舒降之,疗程12周。根据卫生部1988年药物临床研究指导原则规定来做为判断疗效的标准。结果辛伐他汀显效23例,占30.26%,有效43例,占56.58%,无效10例,占13.16%,总有效率为86.84%;舒降之显效25例,占35.71%,有效38例,占54.29%,无效7例,占10.00%,总有效率为90.00%。结论京必舒新和舒降之的临床疗效和不良反应相当,舒降之的成本比京必舒新高,成本-效果比两者相比是京必舒新高,说明京必舒新的治疗方案比舒降之佳。
Objective To evaluate the cost-effectiveness of two oral simvastatin tablets in the treatment of hyperlipidemia. Methods A total of 112 cases of hyperlipidemic patients were randomly divided into two groups according to the cost-benefit analysis of pharmacoeconomics. They were given Jingbishuxin and Shuzheng respectively. The course of treatment was 12 weeks. According to the provisions of the Ministry of Health 1988 Drug Clinical Research guidelines to determine the efficacy of the standard. Results Simvastatin was effective in 23 cases, accounting for 30.26%, effective in 43 cases, accounting for 56.58%, ineffective in 10 cases, accounting for 13.16%, total effective rate was 86.84%; Shufei effective in 25 cases, accounting for 35.71%, effective in 38 cases, Accounting for 54.29%, invalid in 7 cases, accounting for 10.00%, the total effective rate was 90.00%. Conclusions The clinical efficacy and side effects of Jingbishu and Shuzheng are comparable, the cost of Shuzheng is higher than that of Jingbishu, and the cost-effectiveness is Jingbishu new high compared with the two, indicating that Jingbishuxin’s treatment plan Better than Shuzhu.